Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/3/2025

Constipation Management with Fleet Enema and Lactulose

Introduction to Constipation Management

  • The American College of Oncology recommends avoiding Fleet enemas due to serious safety concerns, including perforation, severe electrolyte disturbances, and mortality rates up to 4%, while lactulose is preferred as a safer oral osmotic laxative for chronic constipation management 1

Enema Use and Safety

  • Fleet enemas are contraindicated in patients with neutropenia or thrombocytopenia, paralytic ileus or intestinal obstruction, recent colorectal or gynecological surgery, recent anal or rectal trauma, severe colitis, inflammation, or abdominal infection, toxic megacolon, undiagnosed abdominal pain, and recent pelvic radiotherapy 1
  • Enemas (preferably hyperosmotic saline, NOT Fleet) are first-line therapy only when digital rectal examination identifies a full rectum or fecal impaction 1, 2
  • Small-volume self-administered enemas (hyperosmotic saline) are preferred over Fleet 1
  • Tap water or saline enemas are safer alternatives 3

Lactulose Therapy

  • Lactulose is recommended as a second-line option for chronic constipation after failure of over-the-counter therapies, and is strongly endorsed in systematic reviews 2, 4
  • The initial dose of lactulose is 10-20 g (15-30 mL) daily as a single evening dose to minimize side effects 4, 5
  • Lactulose may be titrated to 40 g (60 mL) daily if needed 4, 6
  • The onset of lactulose effect is expected in 2-3 days 2

Combination Therapy

  • Bisacodyl is recommended as rescue therapy or occasional use alongside lactulose for refractory chronic constipation 5
  • When combining lactulose with bisacodyl, start bisacodyl at the lower dose (5 mg daily) and titrate lactulose based on response before adding or increasing bisacodyl 5

Special Clinical Scenarios

  • For opioid-induced constipation, start stimulant laxative (senna, bisacodyl) with stool softener when initiating opioids, and increase laxative dose when increasing opioid dose 3
  • If constipation persists despite first-line therapy, add lactulose 30-60 mL daily 3

Key Clinical Considerations

  • Monitor for perforation if abdominal pain occurs during enema administration 1
  • Rule out obstruction before any enema use, as perforation risk is significant 1
  • Avoid bulk laxatives for opioid-induced constipation, as they are not recommended 2

REFERENCES

3

adult cancer pain. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

4

Lactulosa-Associated Adverse Effects [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

5

Management of Chronic Constipation with Lactulose and Bisacodyl [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

6

Lactulosa Therapy and Gastrointestinal Side Effects [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025